MG Clinical Trials

3 recruiting

Frequently Asked Questions

Common questions about MG clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 38 trials

Recruiting
Phase 3

PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis

Generalized Myasthenia GravisgMG
Alexion Pharmaceuticals, Inc.12 enrolled13 locationsNCT06607627
Recruiting
Phase 1

ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors

Central Nervous System TumorGlioblastomaCNS Tumor+5 more
Sabine Mueller, MD, PhD208 enrolled6 locationsNCT04732065
Recruiting
Phase 1

Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells

GlioblastomaEGFR Gene MutationMGMT-Unmethylated Glioblastoma+1 more
Hideho Okada, MD, PhD20 enrolled1 locationNCT06186401
Recruiting

Epidemiological Study of Treatment Approaches in AChR-Antibody Positive Generalized Myasthenia Gravis in Russia

Rare DiseasesGeneralized Myasthenia Gravis (gMG)
AstraZeneca450 enrolled3 locationsNCT07247279
Recruiting
Not Applicable

Clinical Study of EVM18001 in the Treatment of Refractory Autoimmune Diseases

SclerodermaMyasthenia Gravis (MG)System Lupus Erythematosus(SLE)
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology12 enrolled1 locationNCT07470151
Recruiting
Phase 1Phase 2

DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma

MGMT-Unmethylated GlioblastomaHigh Grade GliomaMGMT-Methylated Glioblastoma
University of California, San Francisco70 enrolled5 locationsNCT06504381
Recruiting
Phase 4

A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With New-onset Generalized Myasthenia Gravis (gMG)

New Onset Generalized Myasthenia Gravis (gMG)
argenx30 enrolled18 locationsNCT06909214
Recruiting

Investigating the Pathogenic Role of N-glycosylation in AL Amyloidosis: Molecular Bases, Diagnosis, and Treatment

Multiple MyelomaMGUSAL Amyloidosis+1 more
Fondazione IRCCS Policlinico San Matteo di Pavia100 enrolled1 locationNCT07448779
Recruiting
Phase 2

The MIGHT Trial - An Exploratory Clinical Trial of IVIG in Anti-HMGCR Immune Mediated Necrotizing Myopathy

Anti-3-hydroxy-3-methylglutaryl-CoA Reductase (HMGCR) Immune-Mediated Necrotizing Myopathy
University of Alabama at Birmingham12 enrolled5 locationsNCT06599697
Recruiting
Phase 3

Zilucoplan for Severe gMG Exacerbations

Generalized Myasthenia Gravis (gMG)
Miriam Freimer15 enrolled1 locationNCT07215949
Recruiting

ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis

Myasthenia GravisGeneralized Myasthenia Gravis (gMG)Generalized Myasthenia Gravis+3 more
argenx70 enrolled5 locationsNCT07294170
Recruiting

Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome

Smoldering Multiple MyelomaMyelodysplastic SyndromesWaldenstrom Macroglobulinemia+5 more
Dana-Farber Cancer Institute10,000 enrolled7 locationsNCT02269592
Recruiting
Phase 2

ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod

Myasthenia GravisGeneralized Myasthenia Gravis (gMG)Generalized Myasthenia Gravis+3 more
argenx70 enrolled5 locationsNCT07284420
Recruiting
Early Phase 1

Clinical Study on Targeted CD19/BCMA CAR-T Therapy for Autoimmune Diseases

SLESystemic SclerosisNMOSD+4 more
Nanjing Bioheng Biotech Co., Ltd.18 enrolled1 locationNCT06775912
Recruiting
Phase 2

A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma

Smoldering Multiple Myeloma (SMM)Monoclonal Gammopathy of Undetermined Significance (MGUS)
Regeneron Pharmaceuticals116 enrolled13 locationsNCT06140524
Recruiting
Early Phase 1

CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases

Relapsing or Refractory Multiple Sclerosis (MS)Myasthenia Gravis (MG)Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)+1 more
Daishi Tian36 enrolled1 locationNCT07337785
Recruiting

CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot Study

Multiple MyelomaSmoldering Multiple Myeloma (SMM)Monoclonal Gammopathy of Undetermined Significance (MGUS)+2 more
Wake Forest University Health Sciences1,665 enrolled1 locationNCT06644625
Recruiting
Phase 2

Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma

Brain CancerGlioblastomaGlioblastoma Multiforme+4 more
Baptist Health South Florida190 enrolled1 locationNCT06991101
Recruiting

European Myeloma Network (EMN) Sample Project

Multiple MyelomaSmoldering Multiple MyelomaPlasma Cell Leukemia+2 more
European Myeloma Network B.V.6,000 enrolled41 locationsNCT06237803
Recruiting
Not Applicable

Effects of Hip Bump Manipulation Versus Sham Treatment in Healthy Adults

Healthy Adult SubjectsAssessment of Hip Strength, Range of Motion, EMG Activation, and Landing Mechanics in Healthy Subjects
Dominican University New York60 enrolled1 locationNCT07025434